|
Structural Shift: $XLV has transitioned from a multi-month Stage 1 base ($130–137) into Stage 2 advance, breaking above $136 resistance on elevated volume. That volume expansion validates institutional rotation rather than retail momentum. Price is already +6% in a week, which fits the profile of an early markup thrust. Volatility Profile: Post-breakout, $XLV is contracting into an ultra-tight range near highs while volume dries up. That combination with a fresh breakout, rapid expansion, then severe volume contraction, is statistically one of the most reliable precursors to secondary legs higher. The pattern indicates exhaustion of supply, not demand. Breadth & Rotation: What makes this breakout different from defensive “catch-up” moves is its breadth. Participation spans both pharma and biotech, not just large-cap defensive staples. This shows systematic allocation into the sector rather than idiosyncratic stock strength (broad based strength inside the group). Backtests across sectors show that volatility compression within the first 2–3 weeks of a Stage 2 (mark up) breakout tends to precede outsized continuation (3–6x the initial thrust, on average). Wyckoff’s model reads this as the Composite Operator completing accumulation and beginning markup. Want to join 6,000+ traders gaining an edge with our pre-market reports every morning? Subscribe for FREE here submitted by /u/Dense_Box2802 to r/SwingTradingReports |